相关实验视频

Updated: Jun 1, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

奥西默提尼布作为可切除EGFR突变非小细胞肺癌的新辅助疗法:一个现实世界,多中心的回顾性研究

Jialong Li¹, Youyu Wang², Zerui Zhao³

¹Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China (UESTC), Chengdu, China.

Translational lung cancer research

|January 20, 2025

概括

新辅助剂奥西默提尼布对可切除EGFR突变非小细胞肺癌 (NSCLC) 的治疗有前途,其客观应答率为60.5%,安全性良好. 这项现实研究强调了其在临床环境中的潜力.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

奥西默提尼布是一种第三代氨酸激酶抑制剂 (TKI),已批准用于表皮生长因子受体 (EGFR) 突变非小细胞肺癌 (NSCLC).
新辅助疗法旨在改善局部晚期NSCLC的外科治疗结果.

研究的目的:

评估新辅助性奥西默蒂尼布在可切除,局部发达的携带EGFR突变的NSCLC患者中的有效性和安全性.
为了评估客观反应率 (ORR),总生存率 (OS) 和无病生存率 (DFS) 在新辅助性奥西默蒂尼布治疗后.

主要方法:

一个单臂,现实世界,多中心的回顾性研究在中国大陆的十个中心进行.
患有肺腺癌和EGFR突变的患者接受了neoadjuvant osimertinib,随后进行了手术切除.
关键的终点包括ORR,OS和DFS,以及对不良事件 (AE) 的安全评估.

主要成果:

38名患者接受了新辅助性奥西默提尼布;ORR为60.5% (23/38).
94.7% (36/38) 的患者实现了R0切除. 常见的副作用是皮肤刺激 (36.8%) 和胃部不适 (13.2%),没有3级副作用.
两年的OS和DFS率分别为89.2%和87.9%.

结论:

新辅助性 osimertinib 在现实临床环境中在可操作的EGFR突变NSCLC中显示出令人鼓舞的疗效和可接受的安全性.
预计来自NeoADAURAIII期试验的进一步数据将为其有效性和安全性提供额外的见解.

关键词:

新辅助剂是一种新辅助剂.皮肤上生长因子受体 (EGFR)非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.奥西米尔丁尼布 (osimertinib) 是一种

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...